Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05392075 · ClinicalTrials.gov registry record
COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 100
- Enrollment target
NCT05392075 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 100 participants.
The verdict
NCT05392075 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
A novel coronavirus, SARS-CoV-2 (formerly known as the 2019 novel coronavirus \[2019-nCoV\]) was identified as the agent that caused an outbreak of pneumonia (termed COVID-19) in Wuhan, China in December 2019. The virus quickly spread to other countries and on March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic. By March 2021, many nations and organizations embarked on finding a cure or vaccine for this devastating viral infection. The Pfizer COVID-19 mRNA vaccine was the first to obtain emergency use authorization (EUA) from the Food \& Drug Administration (FDA) on December 11, 2020, followed by the Moderna COVID-19 mRNA vaccine on December 18, 2020, and the Janssen COVID-19 viral vector vaccine on February 27, 2021. The mRNA vaccines and the viral vector vaccine are designed based on the spike protein of SARS-COV-2. These vaccines had been administered to millions of Americans prior to July 2021.
Interventions
- BIOLOGICAL Pfizer COVID-19 mRNA vaccine
- BIOLOGICAL Moderna COVID-19 mRNA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2023-08-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05392075
The ClinicalTrials.gov registry entry for NCT05392075 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pfizer COVID-19 mRNA vaccine is the first listed.
NCT05392075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05392075 about?
NCT05392075 is a clinical study titled "COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose". A novel coronavirus, SARS-CoV-2 (formerly known as the 2019 novel coronavirus \[2019-nCoV\]) was identified as the agent that caused an outbreak of pneumonia (termed COVID-19) in Wuhan, China in December 2019. The virus quickly spread to other countries and on March 11, 2020, the World Health Organi...
What is the current status of trial NCT05392075?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2023-03-15. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT05392075?
The interventions under investigation include: Pfizer COVID-19 mRNA vaccine (BIOLOGICAL), Moderna COVID-19 mRNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05392075?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.